FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
Source URL: https://qa1.novartis.us/us-en/news/media-releases/fda-approves-novartis-tobi-podhalertm-certain-cystic-fibrosis-patients-first-and-only-dry-powder-inhaled-antibacterial-us-0
List of links present in page
- https://qa1.novartis.us/us-en/us-en/news/media-releases/fda-approves-novartis-tobi-podhalertm-certain-cystic-fibrosis-patients-first-and-only-dry-powder-inhaled-antibacterial-us-0